I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Activity of Dual SRC-ABL Inhibitors Highlights the Role of ..:
Azam, Mohammad
;
Nardi, Valentina
;
Shakespeare, William C.
...
Proceedings of the National Academy of Sciences of the United States of America. 103 (2006) 24 - p. 9244-9249 , 2006
Link:
https://www.jstor.org/stable/30051928
RT Journal T1
Activity of Dual SRC-ABL Inhibitors Highlights the Role of BCR/ABL Kinase Dynamics in Drug Resistance
UL https://suche.suub.uni-bremen.de/peid=jstor-30051928&Exemplar=1&LAN=DE A1 Azam, Mohammad A1 Nardi, Valentina A1 Shakespeare, William C. A1 Metcalf III, Chester A. A1 Bohacek, Regine S. A1 Wang, Yihan A1 Sundaramoorthi, Raji A1 Sliz, Piotr A1 Veach, Darren R. A1 Bornmann, William G. A1 Clarkson, Bayard A1 Dalgarno, David C. A1 Sawyer, Tomi K. A1 Daley, George Q. PB National Academy of Sciences YR 2006 SN 0027-8424 K1 kinase inhibitors K1 imatinib K1 combination chemotherapy K1 chronic myelogenous leukemia K1 Health sciences K1 Medical sciences K1 Pharmacology K1 Clinical pharmacology K1 Drug resistance K1 Biological sciences K1 Biology K1 Genetics K1 Population genetics K1 Genetic variation K1 Genetic mutation K1 Mutagenesis K1 Medical diagnosis K1 Diagnostic methods K1 Bioassay K1 Mutagenicity tests K1 Biochemistry K1 Enzymology K1 Enzyme kinetics K1 Enzyme activity K1 Binding sites K1 Active sites K1 Pharmaceutics K1 Drug discovery K1 Drug evaluation K1 Preclinical drug evaluation K1 Law K1 Administrative law K1 Economic regulation K1 Commercial regulation K1 Consumer protection regulation K1 Product safety regulation K1 Drug regulation K1 Medical specialties K1 Pathology K1 Pathologic processes K1 Disease course K1 Relapse K1 Point mutation K1 Cytology K1 Cell biology K1 Cells K1 Disease remission JF Proceedings of the National Academy of Sciences of the United States of America VO 103 IS 24 SP 9244 OP 9249 LK http://dx.doi.org/https://www.jstor.org/stable/30051928 DO https://www.jstor.org/stable/30051928 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)